Concepedia

Ruth Columbus

RC

Statistics

Publications

5

Citations

275

H-Index

5

Active since

2004

Affiliations

Walter and Eliza Hall Institute of Medical Research(Current)

Ludwig Cancer Research

Peter MacCallum Cancer Centre

Ruth Columbus is an author at Walter and Eliza Hall Institute of Medical Research specializing in cytokine biology, life sciences, and oncology.

Publications per year

2004–2017

5

Publications

5

Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling

Sandra E. Nicholson, Donald Metcalf, Naomi S. Sprigg et al. · Proceedings of the National Academy of Sciences · 2005 · 96 citations · Full text

Life Sciences, Cell Biology, Cell Proliferation +15

SOCS5 Is Expressed in Primary B and T Lymphoid Cells but Is Dispensable for Lymphocyte Production and Function

Christine Brender, Ruth Columbus, Donald Metcalf et al. · Molecular and Cellular Biology · 2004 · 73 citations · Full text

Life Sciences, Genetics, Immunology +15

Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27

Christine Brender, Gillian M. Tannahill, Brendan J. Jenkins et al. · Blood · 2007 · 66 citations · Full text

Life Sciences, Cell Biology, Immunology +11

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony P. Schwarer et al. · Blood · 2008 · 21 citations

Medicine, Hematology, Oncology +6

A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.

Jayesh Desai, Ben Markman, Sumitra Ananda et al. · Journal of Clinical Oncology · 2017 · 19 citations

Medicine, Oncology, Pharmacology +17

1–5 of 5